10 Best Stocks That Will Always Grow

2. Eli Lilly and Company (NYSE:LLY)

Number of Hedge Fund Holders: 115

Eli Lilly and Company (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products. These products span oncology, diabetes, immunology, neuroscience, and other therapies. Investors are bullish on Eli Lilly and Company (NYSE:LLY) due to its in-demand GLP-1 drugs, used to treat diabetes and obesity, which are still in their early growth stages, and the company’s strong financials.

On April 21, Evan Seigerman, an analyst from BMO Capital, maintained a Buy rating on the company with a $900.00 price target. The analyst opined that Eli Lilly and Company’s (NYSE:LLY) strong position in the pharmaceutical industry supports this buy rating. The company is also preparing for the launch of Orforglipron, which is a promising medication for obesity and type 2 diabetes and brings a positive light to its future operations. The company is ready to satisfy market demand with a notable inventory build-up. The analyst said that this preparation, combined with an anticipated high gross margin, points towards considerable revenue potential for the product.

Eli Lilly and Company (NYSE:LLY) also decided to strategically manufacture the drug’s active pharmaceutical ingredient in the US, relieving it from tariff-related pressures and bolstering its market position. The analyst further remarked that the company has a robust pipeline and a strong oncology franchise, which is expected to support sustained growth and the overall positive outlook for its financial performance. Eli Lilly and Company (NYSE:LLY) is the second best stock that will always grow.

Aristotle Atlantic Partners, LLC highlighted LLY in its Q4 2024 investor letter. Here is what the firm said:

“Eli Lilly and Company (NYSE:LLY) contributed to performance in the fourth quarter. While shares underperformed, our underweight position versus the benchmark resulted in a positive contribution to relative returns. Lilly shares were weak following an uncharacteristic third-quarter earnings miss driven by softer-than-expected sales of its blockbuster diabetes and obesity drugs. The company blamed this partly on wholesaler destocking. Lilly reinforced its view that end demand for the drugs remains strong”.